company background image
ARCT logo

Arcturus Therapeutics Holdings NasdaqGM:ARCT Stock Report

Last Price

US$29.31

Market Cap

US$811.0m

7D

-7.9%

1Y

4.8%

Updated

17 Apr, 2024

Data

Company Financials +

Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Stock Report

Market Cap: US$811.0m

ARCT Stock Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

ARCT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Arcturus Therapeutics Holdings Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arcturus Therapeutics Holdings
Historical stock prices
Current Share PriceUS$29.31
52 Week HighUS$43.81
52 Week LowUS$17.52
Beta2.6
1 Month Change-11.53%
3 Month Change-9.17%
1 Year Change4.79%
3 Year Change-23.35%
5 Year Change291.84%
Change since IPO192.81%

Recent News & Updates

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Recent updates

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

May 11
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space

Apr 25

Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?

Jan 22
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?

Arcturus: Emerging Covid Variants May Provide A Raison D'êTre

Nov 28

Shareholder Returns

ARCTUS BiotechsUS Market
7D-7.9%-5.0%-3.5%
1Y4.8%-1.7%20.2%

Return vs Industry: ARCT exceeded the US Biotechs industry which returned -1.8% over the past year.

Return vs Market: ARCT underperformed the US Market which returned 20.9% over the past year.

Price Volatility

Is ARCT's price volatile compared to industry and market?
ARCT volatility
ARCT Average Weekly Movement8.8%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: ARCT's share price has been volatile over the past 3 months.

Volatility Over Time: ARCT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013180Joe Paynearcturusrx.com

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.

Arcturus Therapeutics Holdings Inc. Fundamentals Summary

How do Arcturus Therapeutics Holdings's earnings and revenue compare to its market cap?
ARCT fundamental statistics
Market capUS$810.96m
Earnings (TTM)-US$29.72m
Revenue (TTM)US$166.80m

4.7x

P/S Ratio

-26.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARCT income statement (TTM)
RevenueUS$166.80m
Cost of RevenueUS$14.95m
Gross ProfitUS$151.85m
Other ExpensesUS$181.57m
Earnings-US$29.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin91.04%
Net Profit Margin-17.82%
Debt/Equity Ratio0%

How did ARCT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.